AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Personalized Medicine in Oncology: Global Partnering Terms & Agreements, 2014 to 2019 - ResearchAndMarkets.com

March 11, 2019

DUBLIN--(BUSINESS WIRE)--Mar 11, 2019--The “Global Personalized Medicine in Oncology Partnering Terms and Agreements 2014 to 2019” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world’s leading companies.

  • Comprehensive directory of personalized medicine in oncology deals since 2014
  • Personalized medicine in oncology contract documents
  • Personalized medicine in oncology agreement terms
  • Personalized medicine in oncology agreement structure
  • Top personalized medicine in oncology deals by value
  • Most active personalized medicine in oncology dealmakers

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Chapters

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2014. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report Scope

This report is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

  • Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2014
  • Analysis of personalized medicine in oncology deal structure
  • Case studies of real-life personalized medicine in oncology deals
  • Access to over 700 personalized medicine in oncology deals
  • The leading personalized medicine in oncology deals by value since 2014
  • Most active personalized medicine in oncology dealmakers since 2014
  • The leading personalized medicine in oncology partnering resources

In this report, the available contracts are listed by:

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

For more information about this report visit https://www.researchandmarkets.com/research/jhhqcn/personalized?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190311005761/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/11/2019 02:45 PM/DISC: 03/11/2019 02:45 PM

http://www.businesswire.com/news/home/20190311005761/en